CLDN18 and neoplasm: To improve affinity, circulation half-life, capacity to mediate anti-tumor cytotoxicity such as ADCC and CDC, the humanized anti-CLDN18.2 VHH 7v3 was fused to human IgG1 Fc to generate a bivalent fusion protein hu7v3-Fc.